Stock Price Movement and Market Context
On 25 Nov 2025, Indo US Bio-Tech's share price touched an intraday low of Rs.112.6, representing a 3.43% decline on the day. This drop extended the stock's losing streak to two consecutive sessions, during which it has recorded a cumulative return of -10.78%. The stock's performance notably lagged behind its sector, which gained 4.27% on the same day, and underperformed by 7.7% relative to the sector's movement.
Indo US Bio-Tech is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates sustained downward momentum over multiple time horizons.
In contrast, the Sensex opened higher at 85,008.93 points, registering a gain of 108.22 points (0.13%) before trading near 84,954.80 points, just 1% shy of its 52-week high of 85,801.70. The Sensex's 50-day moving average remains above its 200-day moving average, signalling a generally bullish market environment. Mid-cap stocks also showed resilience, with the BSE Mid Cap index gaining 0.13% on the day.
Transformation in full progress! This Micro Cap from Auto Ancillary just achieved sustainable profitability after tough times. Be early to witness this powerful comeback story!
- - Sustainable profitability reached
- - Post-turnaround strength
- - Comeback story unfolding
Financial Performance and Profitability Metrics
Indo US Bio-Tech's financial results for the quarter ending September 2025 reveal subdued profitability. The company reported a Profit After Tax (PAT) of Rs.3.45 crores, reflecting a decline of 22.4% compared to the previous four-quarter average. Operating profit before depreciation, interest, and taxes (PBDIT) stood at Rs.4.17 crores, marking the lowest level recorded in recent quarters.
The operating profit to net sales ratio for the quarter was 13.52%, also the lowest in the recent period. These figures highlight a period of constrained earnings generation despite the company's ongoing operations.
Over the past year, Indo US Bio-Tech's stock price has fallen by 56.35%, a stark contrast to the Sensex's 6.03% gain and the BSE500's 4.64% return over the same period. This divergence underscores the stock's relative underperformance within the broader market context.
Operational and Valuation Considerations
Despite the recent price decline, Indo US Bio-Tech exhibits several positive financial characteristics. The company maintains a high Return on Capital Employed (ROCE) of 27.98%, indicating efficient use of capital in generating earnings. Additionally, the debt to EBITDA ratio is 0.91 times, suggesting a manageable level of leverage and a strong capacity to service debt obligations.
Net sales have grown at an annual rate of 31.50%, reflecting healthy long-term revenue expansion. The company’s valuation metrics also present an attractive profile, with a ROCE of 16.4 and an enterprise value to capital employed ratio of 2.3, which is lower than the average historical valuations of its peers in the Other Agricultural Products sector.
Profit growth over the past year has been notable, with profits rising by 43.9%, even as the stock price declined. The price/earnings to growth (PEG) ratio stands at 0.3, indicating a valuation that may be considered low relative to earnings growth.
Why settle for Indo US Bio-Tech ? SwitchER evaluates this Other Agricultural Products micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Shareholding and Industry Position
Indo US Bio-Tech operates within the Other Agricultural Products industry and sector. The majority shareholding is held by promoters, indicating concentrated ownership. The stock’s 52-week high was Rs.386, which contrasts sharply with the current 52-week low of Rs.112.6, illustrating the extent of the price movement over the past year.
The stock’s recent performance has been influenced by a combination of subdued quarterly earnings and broader market dynamics. While the agricultural sector has shown gains, Indo US Bio-Tech’s share price has not mirrored this trend, reflecting company-specific factors impacting investor sentiment.
Overall, the stock’s current valuation and financial metrics provide a detailed picture of its standing within the market and sector, highlighting areas of strength alongside the challenges reflected in its share price trajectory.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
